PharmAust specialises in the relaunch of existing marketed products for oncology applications making the whole development, regulatory and commercialisation process much faster. In addition, PharmAust's other wholly owned subsidiary, Epichem Pty Ltd generates sales of around $1.7M per annum from contract sales to the pharmaceutical industry of synthetic drugs.
Laporan Pasar Australia 10 Februari 2011 memuat: Calzada (ASX:CZD) mengumumkan hasil positif dalam pnelitian cangkok sel (stem cell) manusia untuk pertumbuhan tulang; Latin Resources Limited (ASX:LRS) akan mengakuisisi 14.068 hektar petak-petak pasir besi dan mineral berat kelas dunia di Peru; Northern Star Resources (ASX:NST) mengumumkan hasil produksi emas yang kuat di Australia Barat; PharmAust Limited (ASX:PAA) tengah mengakuisisi proyek logam mulia dan logam dasar bermutu tinggi Eropa.
© 2024 ABN Newswire. All Rights reserved.